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Background: Diffusion-weighted MRI (DWI) has been used in neurosurgical practice mainly to distinguish cerebral
metastases from abscess and glioma. There is evidence from other solid organ cancers and metastases that DWI
may be used as a biomarker of prognosis and treatment response. We therefore investigated DWI characteristics of
cerebral metastases and their peritumoral region recorded pre-operatively and related these to patient outcomes.
Methods: Retrospective analysis of 76 cases operated upon at a single institution with DWI performed pre-operatively
at 1.5T. Maps of apparent diffusion coefficient (ADC) were generated using standard protocols. Readings were taken
from the tumor, peritumoral region and across the brain-tumor interface. Patient outcomes were overall survival and
time to local recurrence.
Results: A minimum ADC greater than 919.4 × 10-6 mm2/s within a metastasis predicted longer overall survival
regardless of adjuvant therapies. This was not simply due to differences between the types of primary cancer
because the effect was observed even in a subgroup of 36 patients with the same primary, non-small cell
lung cancer. The change in diffusion across the tumor border and into peritumoral brain was measured by the
“ADC transition coefficient” or ATC and this was more strongly predictive than ADC readings alone. Metastases with a
sharp change in diffusion across their border (ATC >0.279) showed shorter overall survival compared to those
with a more diffuse edge. The ATC was the only imaging measurement which independently predicted overall survival
in multivariate analysis (hazard ratio 0.54, 95% CI 0.3 – 0.97, p = 0.04).
Conclusions: DWI demonstrates changes in the tumor, across the tumor edge and in the peritumoral region which
may not be visible on conventional MRI and this may be useful in predicting patient outcomes for operated cerebral
metastases.
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Cerebral metastases are an increasingly common prob-
lem with an incidence ten times that of primary brain
tumors and the diagnosis is often made by general radi-
ologists [1,2]. Traditionally MRI has been used for asses-
sing the site and number of metastases, planning for* Correspondence: rzakaria@nhs.net
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unless otherwise stated.surgery or radiosurgery and assessing the response to
therapy [3,4]. Newer MRI techniques have been applied
to help distinguish solitary cerebral metastases from
mimics such as high grade glioma or abscess. One com-
mon example is by measuring the ADC of the lesion but
these readings have more recently been suggested to
have some prognostic value as well as diagnostic [5,6].
When comparing cerebral metastases to glioma consid-
erable attention has focused on the peritumoral region
around the lesion [7-14]. A number of metrics from
DWI including ADC values have been directly measuredLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tastasis determined [15]. The interaction of cerebral metas-
tases and the surrounding brain tissue would be expected
to be crucial to the development of therapies aimed at pre-
venting further spread and invasion. Work on different
methods of invasion - either co-opting existing blood ves-
sels or inducing new blood vessel formation - has already
led to anti-angiogenesis drugs for certain cerebral metasta-
ses [16,17]. Furthermore, the degree of invasion of metas-
tases may affect the margin used in existing treatments
such as surgery and radiosurgery. Despite this potential
clinical importance little has been done to investigate the
invasiveness of cerebral metastases using MRI and nobody
has compared the tumor and peritumoral ADC readings
within a group of metastases. We therefore examined the
MRI characteristics of the tumor, tumor boundary and
peritumoral region for a series of patients with cerebral
metastases who had undergone pre-operative MRI with
DWI followed by surgery. We investigate whether patient
outcomes such as survival and recurrence may be pre-
dicted by different DWI metrics.
Methods
Patients
Patients with a diagnosis of cerebral metastasis were iden-
tified from a histopathology archive spanning the period
2007 – 2012 at a single institution. Records were searched
and cases with a diffusion-weighted MRI scan of the brain
prior to first neurosurgical intervention were selected. Re-
cursive Partitioning Analysis (RPA) [18] class and Graded
Prognostic Assessment (GPA) [19] score were determined;
these are validated predictive measures in cerebral me-
tastasis patients and are based on information such as
control of the primary cancer, extra-cranial metastases,
number of metastases and general health or “performance
status” of the patient. Post-operative clinical course and
oncology care including administration of whole brain
radiotherapy (WBRT) or the use of adjuvant systemic
chemotherapy were recorded from tumor board and pa-
tient notes as these were potential confounding factors.
This study was conducted in accordance with the princi-
ples of the declaration of Helsinki and ethical approval
was granted as an internal project within the institution’s
research tissue bank (National Research Ethics Service #
11/WNo03/2).
Histological analysis
All cases had been reviewed by a consultant neuropath-
ologist in the course of routine clinical care. A histo-
logical diagnosis of metastasis was made and primary
tumor type suggested by review of H & E sections, tumor
specific immuno-histo-cytochemistry and clinical correl-
ation. Where original material was available an additional
automated assessment of cellularity was then made “blind”to the clinical and imaging data. Five separate 200× magni-
fication fields were photographed avoiding gross haemor-
rhage or necrotic material on the H & E slide. Using Image
J software (U. S. National Institutes of Health, Bethesda,
Maryland, USA 2007-2012) with no additional plugins the
percentage nuclear area in each field was determined
using the measure function and a mean taken. A second
independent observer, a cellular pathology researcher of
30 years’ experience then repeated this analysis manually
using a grid and microscopy.
MRI acquisition and analysis
All patients had undergone preoperative MRI brain scans
on different whole body systems at 1.5T with a single
channel head coil at local institutions before transfer to
the Regional Neuroscience Centre (of the 76 cases: 11 on
GE Signa HD, 6 on a GE Discovery, 43 on Philips Achieva
and 16 on a Siemens Avanto). All patients had received at
least 24-48 hours of dexamethasone treatment (of at least
4mg twice daily orally) prior to MR imaging. The imaging
included DWI using one acquisition over 90 seconds
through single-shot echo planar imaging with two b values
of 0 and 1000 second/mm2 in all cases. MR parameters
were similar between scanners and in the following range:
slice thickness 6mm for all, TR 2515 - 3513 msec, TE 71-
94 msec. Trace-weighted imaging and ADC trace maps
were calculated and subsequent readings taken using the
post processing software package GE FuncTool version
4.5.5 (General Electric Co., Maryland, USA). All patients
had also undergone a fast spoiled gradient echo (FSPGR)
or equivalent sequence with gadolinium contrast, again
variable between institutions but most commonly TR 25
msec, TE 6.1 msec, flip angle 20 degrees.
Conventional MRI measures were taken on this post-
contrast T1-weighted sequence including the number of
lesions, maximum diameter on axial slices and volume
(using three orthogonal measurements of diameter). The
largest, operated metastasis only was assessed for those
with multiple lesions (note that in general the cases with
more than one metastasis included a dominant lesion with
only small additional lesions). A number of different as-
sessments of diffusion were made for each metastasis from
the DWI scan and resulting ADC map. Figure 1 demon-
strates the position of regions of interest (ROI) for record-
ing these different ADC metrics. We have previously
reported excellent intra and inter-observer reliability tak-
ing the readings below on this software for 12 of the 76
patients described, with one observer a clinical research
fellow in neurosurgery and the second a clinician of 10
years specialised training in neuroradiology [20].
 ADCmin: The axial slice with the largest area of
tumor was identified and a freehand ROI created
using the tumor border on postcontrast T1-weighted
Figure 1 Measurement of ADC metrics from brain metastases on diffusion-weighted MRI scans. A patient with a history of lung adenocarcinoma
presents with headache and focal neurological deficit. A. Postcontrast T1-weighted sequence demonstrates a right frontal lesion, which was confirmed as
a metastasis after excision. B. An ADC map is generated from B = 0.1000 images using post processing software. On this color map, blue areas represent
low ADC and red higher ADC. C. A freehand region of interest is traced around the tumor border using the postcontrast T1-weighted sequence
as reference on the axial slice with the largest tumor area and those immediately above and below. The ADCmin is the lowest bin of a
histogram of ADC values for all pixels contained within this ROI, averaged over these three slices. Three ROI are placed within the tumor on the
axial slice with the largest area, avoiding necrosis, haemorrhage, cyst and the mean taken to give ADCmean. D. To assess change of ADC across the
tumor border, four ROI are placed starting just inside the tumor border and extending out into the peritumoral region. The slope of the four ADC
values is taken as the “ADC transition coefficient” or ATC. This is repeated in 3 orthogonal directions, avoiding structures such as ventricle or falx and
then repeated on two slices above and below, with the ATC being the mean of the 9 readings.
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above and below using the same method. The software
then gives the maximum and minimum reading for
the given ROI and the mean of the three minimum
values across the three slices was used.
 ADCmean: Three to five circular ROIs of 50 mm2
were placed within the borders of the tumor on
each axial slice, avoiding areas of cyst, necrosis
or haemorrhage. A number of metastases show
haemorrhage and the T1-, T2- weighted and b0
sequence were all assessed for evidence of intratumoralbleeding. Cases were also excluded at this stage if >50%
of the tumor was affected by haemorrhage.
 Peritumoral region: The “peritumoral region” was
taken to be the extent of signal abnormality on the
T2-weighted sequence and “near” as <1 cm from the
tumor edge (as assessed by the co-registered
post-contrast T1-weighted sequence) versus “far”
as ≥1 cm from the edge. Readings of the near
(ADCnear) and far (ADCfar) peritumoral region
were taken using three circular 50 mm2 ROIs on
up to three on contiguous slices.
Table 1 Demographics and treatment summary for the
series (76 patients)
Age at diagnosis/years
(mean & range)
60.6 (35.9 – 81.4)
Gender 36 male : 40 female
Size of operated lesion 27 (9 – 70) Diameter/mm
(Median & range) 8.9 (0.3 – 130) Volume/cc
Disease information Number %
Primary cancer type
Non-small cell lung 36 47.4
Small cell lung 6 7.9
Breast 10 13.7
Melanoma 5 6.6
Gastrointestinal 5 6.6
Urogenital 4 5.3
Ovarian 4 5.3
Squamous cell tonsil 1 1.3
Unknown primary 5 6.6
Location of operated lesion
Supratentorial 64 84.2
Infratentorial 12 15.8
Number of brain mets
Solitary 56 73.7
2 lesions 11 14.5
>2 lesions 9 11.8
RPA class
I 19 25
II 51 67.1
III 6 7.9
GPA score
<1.0 6 7.9
1.5-2 20 26.3
2.5-3.0 39 51.3
>3.0 11 14.5
Neurosurgery
Gross total resection 67 88.2
Partial resection/Biopsy 9 11.8
Adjuvant chemotherapy
for systemic cancer
45 59.2
Whole brain radiotherapy
after neurosurgery
(30 Gy/5# as standard)
56 73.7
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unaffected contralateral white matter and a mean
obtained. The above readings were normalised to
this in order to minimise differences in acquisition
parameters used at different institutions.
 ATC: To assess the metastasis-brain interface, the
gradient of change of the ADC which we have
called the “ADC Transition Coefficient” or ATC
was calculated. As previously described [21] this
involves placing four adjacent ROI (area: 22 mm2)
in a line with the first inside the tumor boundary
and the rest in brain. This was done along orthogonal
trajectories across the anterior, posterior and lateral
tumor tumor borders (avoiding cysts, necrosis
and anatomical boundaries: ventricle, skull vault,
cortex, falx cerebri). The gradient of a linear
regression line (which provided the best fit)
through the four ADC values of the four ROI
was derived and all the trajectories averaged to
generate the ATC.
Follow up & statistical methods
Patients were followed up in regional oncology clinics and
repeat MRI brain taken only if symptoms were present.
Local recurrence or progression was defined as demon-
strable brain disease on a post-operative MRI with appro-
priate clinical correlation and management; patients dying
before that point were censored at the last clear brain scan
(CT or MRI) or last clinical appointment when neurologic-
ally well. Patients who could not be confirmed deceased
were censored at the last clinic appointment that had
been recorded.
Data were analysed and graphs generated using Statistica
version 6 (StatSoft, Inc. 2003) and SPSS version 20.0 (IBM
co., 2011). For analysis of survival, the Kaplan-Meier prod-
uct limit method was used and life tables with survival
curves plotted. Log rank tests were applied to detect differ-
ences between paired groups and Wilcoxon modification
(the Breslow chi square test) used in cases where hazard
did not appear to be proportional. For multivariate analysis
Cox regression was used. Standard tests were used for
comparisons of means and analysis of variance and de-
scriptive statistics, distributions were plotted for all vari-
ables to check assumptions. The level of significance was
set at 95% to reject the null hypothesis and all p-values and
confidence intervals are stated in the Results section.
Results
Clinical outcomes
The demographic details of the cohort of 76 patients are
summarised in Table 1. The median survival from first
diagnosis of cerebral metastasis to death was 9.3 months
(range 0.9 – 34.3 months). 11 cases were censored, mainly
due to death by other causes or loss of follow upsuggesting the length of the follow up period was ad-
equate. It was not appropriate to analyse local recurrence
where the tumor was not fully resected; in the 66 cases
where gross total resection was performed, local recur-
rence occurred in 16 patients (24%) at a median of 17.7
months from presentation (95% CI 10.9 – 24.6). The
Zakaria et al. BMC Medical Imaging 2014, 14:26 Page 5 of 13
http://www.biomedcentral.com/1471-2342/14/26factors associated with overall and progression free sur-
vival, including standard MRI measures such as tumor
size, volume and number, are summarised in Table 2.
ADC readings from the metastases & tumor cellularity
The median ADCmean for cerebral metastases in this
series was 1148.1 × 10-6 mm2/s and the median ADCmin
was 919.4 × 10-6 mm2/s. There were significant differences
in ADC between cerebral metastases from different pri-
mary cancers by one-way ANOVA (F = 2.797, p = 0.025).
On post hoc comparison, this was seen to be because me-
tastases from the so-called “poorly differentiated” cancers
such as melanoma (n = 5) and small cell lung carcinoma
(n = 6) had a lower ADC compared to the metastases from
carcinomas such as breast (n = 10), ovarian (n = 4) and
colorectal (n = 4), as shown in Figure 2.
Tissue was only available for 16 of 76 cases. Cellularity
assessment by ImageJ software as compared to pathologist
assessment appeared to be valid with consistency between
the two observers (intraclass correlation coefficient = 0.61,
p < 0.05). The mean cellularity was negatively correlated
with both the ADCmin and the ADCmean and could be
fitted to either of these with a simple linear regression
model which was highly significant (for ADCmin, F = 7.99,
p = 0.013 and for ADCmean F = 5.56, p = 0.033). ATC was
strongly correlated with cellularity as shown in Figure 3
and was predicted by it using a simple linear regression
model (F = 9.84, p = 0.007).
Relation of tumor ADC to patient outcomes
For survival analysis, the patients were grouped based
on each of the DWI characteristics of their cerebral me-
tastases and the two groups compared. The cases having
a higher than median ADCmin (>919.4 × 10-6 mm2/s)
showed a longer overall survival, median 9.7 months
(95% CI: 8.5 – 11.0) versus those with a lower ADCmin
(median survival 6.2 months, 95% CI: 3.7 – 8.8, Breslow
Chi square 3.87, p = 0.049). There was no difference in
the proportion of patients receiving WBRT in the high
versus the low ADCmin groups that would confound the
effect on survival (Chi square = 3.49, p =0.062). The effect
was also seen if the median ADCmean was used as the
cutoff to define the two groups but was not statistically
significant: OS 9.7 months, 95% CI 7.9 – 11.5 for patients
with metastases having a higher ADCmean (>1148.1 ×
10-6 mm2/s) versus 6.7 months for lower ADCmean, 95%
CI 4.9 – 8.5, Breslow Chi square = 2.83, p = 0.093.
Regarding local control, the median progression free
survival was 11.3 months (95% 5.8 – 16.8) in those cases
with a low ADCmean reading versus 18.4 months (95% CI
11.6 – 25.1) in those with a high ADCmean (Log rank test,
Chi Square 4.263, p = 0.039). This is illustrated in Figure 4.
This effect was also seen when the median ADCmin was
used as the cutoff to define the two groups but did notreach statistical significance (high ADCmin, progression
free survival 18.4 months, 95% CI 13.2 – 23.6 versus low
ADCmin, progression free survival 11.3 months, 95% CI
8.4 – 14.3, Log rank = 2.93, p = 0.087).
Non-small cell lung cancer metastases represented the
largest group of cases from a single primary cancer (al-
though further detail was not known, even within this
group there would be expected to be subdivisions such as
adenocarcinoma and squamous cell carcinoma; it is at
least more uniform than any previous analysis which in-
cludes multiple different primary sites) and this subgroup
of 36 cases was therefore analysed separately in order to
confirm that the ADC has value in and of itself as a prog-
nostic marker not simply as a surrogate of the primary
tumor type. Overall survival was significantly longer for
non-small cell lung cancer cases with a high tumor
ADCmin at 9.7 months (CI 6.7 – 12.6) versus 5.3 months
(CI 2.2 – 8.5) for those with low ADCmin, Log rank Chi
square = 4.008, p = 0.045. The same effect was observed
and was significant using median ADCmean as the cutoff
because higher ADC group had median OS 10.5months
(CI 7.7 – 13.2) versus 5.8 months, (CI 3.2 – 8.4) for low
ADC group, Log rank = 4.135, p = 0.042.
ADC changes at the brain-metastasis interface
The change in diffusion across the brain-metastasis inter-
face might be expected to relate to changes at the cellular
level and hence even reflect tumor-stroma interactions.
We have previously devised and applied a measure of the
changing ADC at the metastasis-brain boundary, called
the “ADC transition coefficient” or ATC. This could be
calculated for 70 cases (as described in the Methods
there needs to be a boundary to surrounding tissue to
measure and calculate a reading) and found the ATC to
have a median value of 0.279 (range 0.063 - 0.453).
The ATC showed no relationship to the primary cancer
type on one-way ANOVA (df 11, F = 0.348, p = 0.9) and
weak negative correlation with ADCmean and ADCmin
(Pearson correlation coefficient -0.39 and -0.33 respectively,
p > 0.05) suggesting it was measuring a different feature ra-
ther than just acting as a surrogate of the other ADC char-
acteristics or the primary cancer.
The group was divided into two based on the ATC,
and those patients with a metastasis showing high ATC
(> median) and therefore a sharp boundary on the ADC
map had a shorter overall survival 6.8 months (95% CI
5.3 – 8.4) as compared to those with a low ATC and
hence diffuse boundary on ADC map (11.2 months, 95%
CI 8.3 – 14.0, Log rank Chi-Square = 4.19, p = 0.041).
This is illustrated more clearly in the conventional MRI
scans and accompanying ADC maps in Figure 5. There
was also a tendency to earlier local recurrence in high
ATC cases versus low ATC but this was not statistically
significant (shown in Table 2).
Table 2 Clinical and radiological factors associated with survival and progression
Factor Overall survival
median/months
95% CI Significance
on univariate
analysis
Progression
free survival
median/months
95% CI Significance
on univariate
analysis
GPA score
< 1.0 5.3 0.4 – 10.2 0.306 Not reached 0.936
1.5-2 6.8 0 – 14.0 18.4 -
2.5-3.0 9.3 8.0 – 10.6 17.8 6.1 – 29.4
> 3.0 9.8 7.8 – 11.7 13.1 9.0 – 17.2
RPA class
I 14.0 6.1 – 22.0 0.030* 17.7 14.6 – 20.9 0.636
II 8.4 5.1 – 11.8 13.1 9.7 – 16.6
III 2.0 0 – 6.2 Not reached
Primary cancer (too many censored
cases in each category
for analysis)Lung non-small cell 9.2 2.0 – 19.8 0.061 Not reached
Lung small cell 4.5 1.0 – 28.9 10.5 -
Breast 10.4 0.9 – 21.2 9.2 5.6 – 12.9
Colorectal 6.8 5.3 – 12.3 Not reached
Melanoma 11.5 2.4 – 14.7 7.3 4.9 – 9.7
Urological 4.0 1.1 – 9.6 Not reached
Ovarian 11.2 4.7 – 30 17.8 -
Unknown 5.6 1.5 – 22.8 18.4 -
Location
Supratentorial 9.6 8.2 – 11.1 0.070 17.7 10.8 – 24.6 0.872
Infratentorial 4.4 0 – 10.1 Not reached
Surgery
Biopsy 5.9 0 – 16.4 0.091
Resection 9.6 8.1 – 11.0
Adjuvant whole brain radiotherapy
Yes 10.5 8.9 - 12 0.000* 17.7 10.9 – 24.6 0.000*
No 2.4 1.5 – 3.3 Not reached
Adjuvant chemotherapy
Yes 10.5 8.2 – 12.7 0.001* 15.7 10.7 – 20.6 0.240
No 5.3 3.0 – 7.6 Not reached
Diffusion MR metrics
ADCmin > 919 × 10-6 mm2/s 9.7 8.5 – 11.0 0.049* 18.4 13.2 – 23.6 0.087
ADCmin < 919 × 10-6 mm2/s 6.2 3.7 – 8.8 11.3 8.4 – 14.3
ADCmean > 1148 × 10-6 mm2/s 9.7 7.9 – 11.5 0.093 18.4 11.6 – 25.1 0.039*
ADCmean < 1148 × 10-6 mm2/s 6.7 4.9 – 8.5 11.3 5.8 – 16.8
ATC > 0.279 6.8 5.3 – 8.4 0.041* 11.3 8.2 – 14.4 0.072
ATC < 0.279 11.2 8.3 – 14.0 Not reached
Standard MRI measures
Diameter > 30 mm 6.7 2.4 – 11.0 0.246 13.1 9.7 – 16.6 0.551
Diameter < 30 mm 9.6 8.8 – 10.4 17.8 14.7 – 20.1
Volume > 8.9 cc 6.7 1.9 – 11.5 0.077 13.1 9.2 – 17.1 0.158
Volume < 8.9 cc 9.6 8.8 – 10.3 17.8 13.7 – 21.8
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Table 2 Clinical and radiological factors associated with survival and progression (Continued)
Solitary 8.42 5.3 – 11.5 0.101 15.7 10.3 – 21.0 0.673
2 lesions 14.1 10.7- 17.6 11.3 0.85 – 21.8
> 2 lesions 6.1 5.1 – 12.2 Not reached
Log rank tests were applied to detect differences between categories with Wilcoxon modification (the Breslow chi square test) in cases where hazard did not
appear to be proportional. In all comparisons *indicates p < 0.05.
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Initially we did not find a large variability in the ADC
around a given metastasis and for the 76 cases together, the
mean “near” peritumoral ADC was 2028.4 × 10-6 mm2/s
which did not differ significantly from the mean “far” peri-
tumoral ADC of 1994.9 × 10-6 mm2/s. There was no sig-
nificant variation of either variable by primary cancer
type on one-way ANOVA. There was also no significant
differences in patient outcomes (overall survival, local re-
currence) when the cohort was divided into two “high”
and “low” groups by either near peritumoral ADC, far
peritumoral ADC or near:far ADC ratio and actuarial sur-
vival analysis performed.Figure 2 ADC values of 76 brain metastases by primary cancer of o
shown +/- standard error and *indicates significant difference from the
diagnoses were confirmed by neuropathology assessment after biopsy oWhen visually inspecting the ADC maps for the 76
cases, however, it appeared that for a minority of metasta-
ses, in particular those from melanoma primaries, diffusion
did vary greatly between the near and far peritumoral re-
gions. The values of ADC at each point going out from the
tumor towards normal white matter were plotted for illus-
trative purposes to show the “ADC signature” for that type
of metastasis and an example of this is given in Figure 6. It
was relevant to directly compare such patterns of ADC
change in two types of cancer known to show differing
mechanisms of brain invasion, as outlined in Discussion.
The ratio of the near and far ADC values were therefore
calculated for metastases of melanoma and non-small cellrigin. The mean ADCmin value for each primary cancer type is
group at p < 0.05 by independent student t-test. All histological
r resection and correlation with clinical data.
Figure 3 The gradient in change of ADC across the tumor border on preoperative DWI for brain metastases, called the ATC (see Methods)
was strongly predictive of the cellularity, as shown in the scatterplot above. Cellularity was assessed in a semi-automated fashion using
ImageJ software from five different high power fields and ATC measured as shown in Figure 1. The line shows a simple linear regression model
which was highly significant (ATC = 0.007* mean cellularity + 0.07, ANOVA F = 9.84, p < 0.001).
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this ratio was significantly higher (independent 2-tailed t
test = 2.259, df 36, p = 0.03).
Multivariate analysis
A Cox regression model was generated using the radio-
logical and non-radiological factors found to be significant
discriminators of overall survival in univariate analysis.
Only post-operative WBRT (hazard ratio 3.1, 95% CI 1.5 –
6.8, p =0.004) and low ATC (hazard ratio 0.54, 95% CI
0.3 – 0.97, p = 0.04) were found to be significantly asso-
ciated with prolonged overall survival in this series. Multi-
variate analysis was attempted for progression free survival
however modelling was inaccurate with large errors due to
the high proportion of censored data (only 24% of the
group or 16 cases developed local recurrence, as stated).
Discussion
The value of tumor ADC in cerebral metastases
This is the largest examination of diffusion-weighted
MRI and cerebral metastases to date. The numerical
values for tumor ADC are in line with previous investi-
gations of cerebral metastases which would be expected
given the standard methods and protocols used for im-
aging and analysis [6,7,10,13,14,22,23]. We used a varietyof methods of taking measurements from the ADC maps
so as not to miss an effect due to our measurement
technique. We have confirmed that ADC varies be-
tween cerebral metastases from different primary cancers
but like others not sufficiently to distinguish the individual
primary cancer type [24,25]. This may be because the
ADC reflects more general characteristics like cellularity.
In support of this, ADC values were lower for the group
of poorly differentiated metastases of melanoma and small
cell lung cancer compared to the group of metastases
from carcinomas (including breast and colorectal). We
also corroborate the suggestion that tumor cellularity is
inversely related to tumor ADC for a sample of our cases
where tissue was available, whether measured by the
minimum or the mean ADC. This is logical as more
densely packed cells would broadly be expected to re-
strict diffusion, with the caveat that this coarse method
of calculating ADC maps does not reflect the more
subtle distinctions between intra and extracellular diffu-
sion that others have derived using more advanced
models in animals [26,27]. However it has also been
shown in cerebral metastases post mortem that a dense
extracellular matrix correlates with low ADC, similarly
suggesting a role for the tumor-stroma interaction we
discuss later in human cases [6].
Figure 4 ADC of the metastasis predicts subsequent patient outcomes. Cases such as that in A. an enhancing lesion with hypo-intense DWI
signal and higher than median ADC were compared to those such as B. an enhancing lesion but with hyper-intense DWI signal and corresponding
low readings on ADC map. C. The largest group of metastases (n = 36) from a single primary - lung non-small cell carcinoma – were stratified into two
groups by these readings of tumor ADC. Overall survival was significantly longer for cases with a high tumor ADCmean (10.5 months, CI 7.7 – 13.2)
versus a low tumor ADCmean (5.8 months, CI 3.2 – 8.4, Log rank = 4.135, p = 0.042). D. For the 66 cases where gross total resection was performed,
local recurrence in the brain occurred in 16. Metastases with a higher ADC showed significantly longer progression free survival, 18.4 months (95% CI
11.6 – 25.1) versus 11.3 months (95% 5.8 – 16.8) in those with a low ADCmean (Log rank test, Chi Square 4.263, p = 0.039).
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this smaller study [6] that the pre-operative mean ADC
of a cerebral metastasis is correlated with subsequent
overall patient survival and we have now demonstrated
this for a single tissue type; non-small cell lung carcinoma.
We did not find that this effect persists in multivariate
analysis. This may be due to including oligometastatic dis-
ease in this series but it seemed reasonable to include such
cases as they all had a single larger, dominant lesion and
we included the number of lesions as a confounding factor
as it forms part of the GPA score. These findings that
ADC predicts prognosis are in keeping with a number of
reports from other brain tumors where DWI has been ap-
plied to predict stage and prognosis [28-30] as well as
other organ systems such as renal, rectal, head and neck
or cervical tumors [31-35]. In our series, in addition to
whole brain radiotherapy - which is a treatment – it was
only the change in diffusion across the tumor boundary
which we call the ADC transition coefficient (ATC) that
independently predicted the overall survival in multivari-
ate analysis despite all other clinical factors. Why should
this be?The brain-metastasis interface
We have shown that changes in ADC across the brain-
metastasis interface can be used to define the “sharpness”
of this boundary, yielding additional information compared
to assessing the boundary on postcontrast T1-weighted se-
quences alone. Rather than a low ATC and diffuse bound-
ary on ADC map being associated with poor survival - as
one might expect if this simply represented a more infiltra-
tive pattern of growth - the reverse was true. A high ATC
may in fact reflect high cellularity at the leading edge of
the metastasis and hence greater tendency to recur locally.
In support of this, the ATC was strongly linearly related to
tumor cellularity in a sample of cases where tissue was
available. One might predict that these cases may benefit
from more aggressive local adjuvant treatments, such as
wider surgical margins or radiosurgery “boost” to the cav-
ity. Previous work on the interface between cerebral metas-
tases and the surrounding brain has been conducted using
histological methods on surgically resected or post mortem
specimens [36-38] and this has certainly suggested that
there are different patterns and depths of invasion, even if
this has not been related to clinical outcomes. Furthermore,
Figure 5 Analysing the brain-metastasis interface. Metastases could be stratified by the sharpness of the tumor border on ADC maps. Panel
A. demonstrates a lesion with a high ATC or “ADC transition coefficient” implying a sharp border. This type of metastasis tended to have a high
cellularity (H & E section x200). Panel B. demonstrates a case which looks superficially similar on postcontrast T1-weighted sequence but actually
has a much more diffuse border on the ADC map and hence a low ATC, with lower cellularity. C. These metastases differ in their outcomes and
the cases with a high ATC (> median) and therefore a sharp boundary had a shorter overall survival 6.8 months (95% CI 5.3 – 8.4) as compared to
those with a low ATC and hence diffuse boundary (11.2 months, 95% CI 8.3 – 14.0, Log rank Chi-Square = 4.19, p = 0.041). This effect was significant
even in multivariate analysis incorporating traditional clinical predictors.
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prove clinical survival [39] and that ADC changes across
the border of another brain tumor - oligodendroglioma -
may predict growth pattern and aggressiveness [21]. Novel
therapies acting at the brain-metastasis interface are being
developed [40], therefore more accurate non-invasive,
radiological methods may be needed to assess the degree
of invasion of cerebral metastases and characterise the
tumor boundary changes seen at diffusion-weighted MRI.
The peritumoral region
The MRI characteristics of the peritumoral region of cere-
bral metastases have previously been examined only in
order to distinguish these tumors from glioma and abscess
[15,41,42]. In this context the contrast enhancing margin
has been taken as the reference and the near peritumoral
region has been taken as being within 1 cm of this edge.
We have shown that for some metastases the ADC varies
considerably from the core of the tumor, toward the lead-
ing edge and out into both the near and far peritu-
moral regions. It is known that the extent of T2-weighted
oedema (over 1 cm in width from the tumor edge +/-
midline shift) may be a prognostic factor [43] and the dif-
ferent peritumoral ADC values in different metastases
may be due to differences in the intensity of peritumoral
oedema and/or underlying vascular permeability due to
different patterns of infiltration. Melanoma metastases, for
example, showed a significantly higher near:far peritumoral
ADC ratio than non-small cell lung cancer metastases inthis study. These tumors are known to show different pat-
terns of growth [16]; melanoma metastases co-opt existing
vessels whereas lung adenocarcinoma (the most common
non-small cell lung cancer) stimulates neoangiogenesis
and the pattern of peritumoral ADC changes might reflect
this. In animal models peritumoral ADC changes are seen
before postcontrast T1-weighted enhancement as micro-
metastasis formation and multiplication occurs [44]. Tissue
samples with paired radiological data would be needed to
confirm what the correlate of these ADC changes are in
humans, however it is unlikely that one would be practic-
ally able to gather tissue from deep within the region of
peritumoral oedema around a metastasis as has been done
for glioma [45]. The brain-metastasis boundary is there-
fore a more fruitful area to investigate in the first instance.
One could ask what the biological differences in pattern of
infiltration, vascularity, protein expression and inflamma-
tory response are around metastases with a sharp versus a
diffuse ADC border and therefore could the ATC or simi-
lar measures of diffusion change be used as a surrogate of
such biological activity.
Limitations and future directions
A prospective study with image guided sampling in the
course of routine resection would provide matched MRI
and tissue data within and around cerebral metastases (as
has been done with glioma and in animal models [44])
and should confirm the underlying biological changes
which account for the ADC patterns seen. This was a
Figure 6 Changes in diffusion around a brain metastasis. A solitary metastasis in a patient with known renal cell carcinoma is shown in
(A) with a clear boundary, necrotic centre and surrounding oedema, visible on the T2-weighted sequence. What is happening in the region
around the metasasis? There is substantial evidence that this region consists of vasogenic oedema, higher diffusion and lower perfusion when
compared to high grade glioma for example, but what about comparing within a group of metastases. (B). One can place serial regions of
interest and measure and plot the ADC changes from the necrotic centre of the tumor through the leading edge and into the peritumoral
regions. (C) Box and whisker plots showing the median, interquartile range and outliers for ADC readings in and around melanoma (n = 5) and
non-small cell lung cancer (n = 36) metastases demonstrates differences in this ADC signature between the two groups and within them but the
biological correlate of these differences needs to be investigated.
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sally available and was in paraffin embedded blocks from
non-specific areas of the tumor, hence such an analysis
was not possible. This study only examined ADC maps
as more gradient directions were not available (again
due to the MRI data having already been acquired and
the analysis being retrospective) but ideally, more MRI
sequences would be analysed pre-operatively including
assessment of anisotropic diffusion, via fractional anisot-
ropy. Disruption of white matter tracts is traditionally
only seen in infiltrating tumors such as glioblastoma [46]
and it would be important to observe if more infiltrativebrain metastases as described pathologically [47] show
different fractional anisotropy values in the peritumoral
region. These findings are also cautioned by the need for
validated, reproducible methods when measuring DWI
metrics. In particular, we found differences in “tumor
ADC” between measuring whole tumor values, mini-
mum values and taking the mean of multiple ROIs. We
have previously described good inter and intra-observer
agreement measuring ADC metrics with various ROI
methods in brain metastases on different post processing
platforms [20]. A logical step would be to validate these
metrics – in particular the ATC - on a separate, larger
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ventional predictive models such as RPA and GPA.
Different MRI protocols from different vendors have
had to be combined in this series due to a need for suffi-
cient power for survival analysis. Again, data gathered in
a prospective fashion on a single scanner with uniform
protocols would be preferable. However ADC maps are
theoretically and practically relatively resistant to varia-
tions in MR parameters (for example diffusion is insensi-
tive to B1 errors). More sophisticated DWI parameters,
including assessment of anisotropic diffusion (fractional
anisotropy) which we would intend to study next, present
more variation between centres. The use of phantoms
and comparison of normal white matter readings may be
needed to reduce and quantify between centre variation
respectively [48]. The precise dosing and timing of cor-
ticosteroid therapy could also be established in a prospect-
ive series and effects on DWI parameters assessed.
The prevalence of intratumoral haemorrhage in many
brain metastasis types is a problem and reduces the num-
ber of cases which are suitable for analysis (cases with
overwhelming haemorrhage were excluded as stated in the
Methods) as well as potentially making these findings less
relevant to cases which tend to bleed such as melanoma
and renal. Nonetheless a reasonable spread of common
histological types was used here. Newer systemic therapies
for treating cerebral metastases may lead to significant dif-
ferences in survival between different tumor types and
comprehensive clinical data with large numbers would be
needed to stratify cases in future, for example by HER2 re-
sponsiveness in breast carcinoma metastases. This makes
large scale biomarker studies practically difficult and the
need for collaboration between centres paramount.
Conclusions
Diffusion-weighted MRI demonstrates changes in the
tumor, across the tumor edge and in the peritumoral re-
gion which may not be visible on standard MRI and this
may be useful in predicting patient outcomes for cere-
bral metastases.Abbreviations
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